Neurology Xagena
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tecfidera 120 mg and 240 mg ...
More than 80% of individuals with multiple sclerosis ( MS ) experience a relapsing-remitting disease course. Approximately 10 years after disease onset, an estimated 50% of individuals with relapsing- ...
ENDORSE is an ongoing, 5-year, dose-blind extension of the phase 3 DEFINE and CONFIRM studies evaluating the efficacy and safety of delayed-release Dimethyl fumarate ( DMF ) in relapsing-remitting mul ...
Five-year results from the ENDORSE phase 3 extension study have shown Dimethyl fumarate ( Tecfidera ) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting ...
The purpose was to report the effects of delayed-release Dimethyl fumarate ( DMF; also known as gastro-resistant DMF ) on the number of relapses requiring intravenous ( IV ) steroids and multiple scle ...
Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more than 2 million people worldwide. The disease usually starts in early adulthood, but the ...
There are increasing data that delaying starting disease-modifying drugs and/or routinely stopping all disease-modifying drugs prepregnancy or immediately postconception is associated with increased r ...
